A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes

Ingunn O. Lund, Gabriele Fischer, Gabrielle K. Welle-Strand, Kevin E. O'grady, Kimber Debelak, William R. Morrone, Hendrée E. Jones

Research output: Contribution to journalArticlepeer-review

Abstract

Given that buprenorphine + naloxone is prescribed for opioid-dependent pregnant women, it is important to examine the extent to which it differs from buprenorphine alone, methadone, or methadone-assisted withdrawal on neonatal and maternal outcomes. Summary statistics on maternal and neonatal outcomes were collected from 7 previously published studies examining treatment for opioid-dependent pregnant women that represented a range of research methodologies. Outcomes from these studies were compared to the same outcomes for 10 women treated with the combined buprenorphine + naloxone product. There were no significant differences in maternal outcomes for buprenorphine + naloxone compared to buprenorphine, methadone, or methadone-assisted withdrawal. Preliminary findings suggest no significant adverse maternal or neonatal outcomes related to the use of buprenorphine + naloxone for the treatment of opioid dependence during pregnancy. However, further research should examine possible differences between buprenorphine + naloxone and buprenorphine alone or methadone in fetal physical development.

Original languageEnglish (US)
Pages (from-to)61-74
Number of pages14
JournalSubstance Abuse: Research and Treatment
Volume7
DOIs
StatePublished - 2013

Keywords

  • Buprenorphine
  • Methadone
  • Neonates
  • Opioid dependence
  • Pregnancy

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: Maternal and neonatal outcomes'. Together they form a unique fingerprint.

Cite this